Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…Abstract Number: 2495 • ACR Convergence 2024
Diffuse Alveolar Hemorrhage in Patient with ANCA-associated Vasculitis AndInterstitial Lung Disease
Background/Purpose: The association of interstitial lung disease (ILD) and microscopic polyangiitis (MPA) is increasingly recognized. The implications of ILD as it relates to clinical outcomes…Abstract Number: 0637 • ACR Convergence 2023
Comparison of Four Risk Stratification Models for Prediction of Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in the EUSTAR Cohort
Background/Purpose: The 2022 ESC/ERS Guidelines recommend comprehensive risk stratification at diagnosis of pulmonary arterial hypertension (PAH) to guide optimized management.1Several risk stratification tools have been…Abstract Number: 1701 • ACR Convergence 2023
Treatment Regimens and Mortality in Systemic Sclerosis-associated Pulmonary Arterial Hypertension in Light of the 2022 ESC/ERS Guidelines
Background/Purpose: The 2022 ESC/ERS Guidelines recommend upfront combination therapy for low- and intermediate-risk, and triple therapy for high-risk patients with systemic sclerosis (SSc)-associated pulmonary arterial…Abstract Number: 2353 • ACR Convergence 2023
Role of Insulin-like Growth Factor Binding Protein-7 (IGFBP7) in Pulmonary Hypertension Pathogenesis and as a Biomarker Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Background/Purpose: Systemic sclerosis (SSc, scleroderma) is an autoimmune connective tissue disease that causes autoimmunity, vascular dysfunction, and fibrosis of the skin, lungs, and other organs.…Abstract Number: 0638 • ACR Convergence 2023
Application of the 2022 European Society of Cardiology (ESC) Risk Assessment Model in Australian and Singaporean Systemic Sclerosis Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH)
Background/Purpose: Pulmonary arterial hypertension (PAH) patients can be stratified as low, intermediate, or high risk of 1-year mortality based on clinical, biochemical and haemodynamic prognostic…Abstract Number: 1704 • ACR Convergence 2023
Esophageal Mucosal Erosions Can Predict the Deterioration of Lung Function over a Four-year Follow-up Period and Long-term Mortality in Patients with Interstitial Lung Disease Associated with Scleroderma
Background/Purpose: Interstitial lung disease (ILD) is a major cause of morbidity and disease-related death in systemic sclerosis (SSc). Esophageal disease is common in SSc, and…Abstract Number: 2355 • ACR Convergence 2023
Proteome-based Stratification of Therapeutic Target Population for MT-6194 in Systemic Sclerosis with Pulmonary Arterial Hypertension
Background/Purpose: SSc-related pulmonary arterial hypertension (SSc-PAH) is the one of the leading causes of death in SSc. Early diagnosis and effective therapy for SSc-PAH may…Abstract Number: 0657 • ACR Convergence 2023
The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis
Background/Purpose: Cardiopulmonary involvement (CPI) in systemic sclerosis (SSc) is associated with significant morbidity and mortality. Early detection and timely treatment is warranted. The Six-minute walk…Abstract Number: 1714 • ACR Convergence 2023
Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling
Background/Purpose: Pulmonary hypertension (PH) is a severe, progressive disorder characterized by elevated pulmonary artery pressures, right ventricular hypertrophy, and increased mortality. We previously demonstrated that…Abstract Number: 2364 • ACR Convergence 2023
Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis
Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…Abstract Number: 0684 • ACR Convergence 2023
Report on Twelve Patients with Diffuse Alveolar Hemorrhage in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis
Background/Purpose: Although respiratory tract involvement in ANCA-associated vasculitis (AAV) is frequent and associated with increased mortality, studies focusing on diffuse alveolar hemorrhage (DAH) in AAV…Abstract Number: 1718 • ACR Convergence 2023
Longitudinal Quantification of Bone Erosions, Pulmonary Disease, Pain, Gait and Sarcopenia to Holistically Assess Decreased Ad Libitum Physical Activity and Effects of Exercise in the TNF-Transgenic Murine Model of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by pain, swelling, and joint destruction that decreases mobility.RA patients also suffer from pulmonary disease…Abstract Number: 2450 • ACR Convergence 2023
Gene by Respiratory Disease Interactions Associated with Developing Rheumatoid Arthritis
Background/Purpose: Cigarette smoking, textile dust, and occupational inhalants all strongly interact with the Human Leukocyte Antigen (HLA) shared epitope for risk of seropositive RA. Recently,…Abstract Number: 0789 • ACR Convergence 2023
Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis
Background/Purpose: Peripheral blood leukocyte telomere length (PBL-TL) has been associated with disease and organ specific morbidity and mortality in conditions associated with pulmonary fibrosis including…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 12
- Next Page »